Good morning, everyone, and welcome to another working week. Those of you on our side of the pond had, of course, an extended respite thanks to a federal holiday, and we hope your time was relaxing and invigorating, because that oh-so-familiar routine of deadlines, meetings, and the like has now returned. There is only one thing to do in such situations: reach for a cup of stimulation. Our choice today is macadamia nut. Feel free to join us with whatever flavor you prefer. Or perhaps a spot of tea is in order. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Hope you have a smashing day and do keep in touch …

An AstraZeneca (AZN) immunotherapy won approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors, Reuters tells us. Known as Imfinzi, the drug will be given to non-small cell lung cancer patients with inoperable mid-stage disease that has not spread widely, the first immunotherapy to be approved in this setting. The endorsement gives AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have approval for tackling advanced or metastatic disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy